Key clinical point: Upadacitinib significantly improved the signs and symptoms of active ankylosing spondylitis in a phase 2/3 study.
Major finding: An ASAS 40 response at week 14 was achieved by 51.6% of patients treated with upadacitinib versus 25.5% of placebo-treated patients.
Study details: The randomized, placebo-controlled, phase 2/3 SELECT-AXIS 1 study of 187 patients.
Disclosures: AbbVie, which markets upadacitinib, funded the study. Dr. van der Heijde disclosed financial relationships with AbbVie and 20 other pharmaceutical companies. Many other authors also reported financial relationships with industry, including AbbVie.
van der Heijde D et al. Arthritis Rheumatol. 2019;71(suppl 10), Abstract 2728.